Sana Biotechnology, Inc. is a clinical-stage biotechnology company dedicated to harnessing the potential of cell engineering and gene therapy to develop curative treatments for a wide array of human diseases. Founded in 2018 and headquartered in Seattle, Washington, with a major research presence in Cambridge, Massachusetts, Sana has built a versatile platform for creating, delivering and regulating engineered cells and genetic material. The company’s mission is to advance the transformation of biological medicines by addressing the root causes of disease through precise, durable interventions.
At the heart of Sana’s approach are two complementary technology platforms: ex vivo cell engineering and in vivo gene delivery. The ex vivo platform involves the isolation, genetic modification and reinfusion of a patient’s own cells to fight hematological and immunological disorders. The in vivo platform enables targeted delivery of gene-editing machinery directly into the body to correct disease-causing genetic defects. By leveraging proprietary delivery vehicles and gene regulation tools, Sana aims to create therapies that can be administered with the simplicity of traditional pharmaceuticals but the durability of cell and gene therapies.
Sana’s pipeline spans multiple therapeutic areas, including blood disorders, metabolic diseases, oncology and ophthalmology. Several early-stage programs have advanced into human clinical trials, reflecting the company’s commitment to rigorous development and robust safety evaluation. Research and development efforts benefit from collaborations with academic institutions and industry partners, expanding Sana’s geographic reach and enabling access to specialized expertise in regulatory affairs, manufacturing and patient care.
Under the leadership of CEO Steve Harr, a former executive at leading life sciences firms, Sana has assembled a seasoned management team with deep experience in molecular biology, translational research and commercial strategy. The board and scientific advisory council include experts in gene editing, stem cell biology and immunotherapy, ensuring that Sana’s strategic direction is guided by cutting-edge science and best practices in biopharmaceutical development. Together, this leadership aims to bring transformative therapies to patients around the world.
AI Generated. May Contain Errors.
Free SANA Stock Alerts